Bacterial infection is the focus of burn treatment. Many patients are aggravated by bacterial infection, resulting in amputation or even death.
Pseudomonas aeruginosa accounted for a high proportion of bacterial infection. The multidrug -resistance of it reduces the efficacy of antibiotics.
We use bacterial cellulose, a new biomaterial, loaded with a specifically killing P. aeruginosa protein to treat infected burn patients. Gluconacetobacter xylinus ATCC53582 has been designed by the tools of synthetic biology to produce bacterial cellulose under near-infrared light control and release the antimicrobial protein under blue light.
Our product is in the form of live bacteria. We devote ourselves to help burn patients in need.